How can we overcome ibrutinib resistance?
GCLLSG trial results to be presented at the 2016 ASH Annual Meeting
Combining radiotherapy and the immune system in lymphomas
T-Cell engaging treatment in AML
Combining ublituximab with the novel PI3K inhibitor TGR-1202 for CLL